GSK PLC on Monday said the European Commission has expanded approval for its drug Jemperli, in combination with chemo ... Subscribe now to see this Premium News article from Alliance News ...

GSK and the University of Oxford have entered a new research partnership to launch an immuno-prevention programme to explore ...

GSK’s Jemperli has claimed an edge over its main rival in the endometrial cancer therapy market after showing improved overall survival in a broad patient population in the RUBY trial.

The new approval bolsters AZ's position in what is becoming a battle with GSK and MSD in first-line endometrial cancer, with Imfinzi and Imfinzi/Lynparza pitted against the GSK's Jemperli ...

Also in Europe, officials have endorsed GSK's Jemperli to treat all adult patients with primary advanced or recurrent endometrial cancer, including those with mismatch repair proficient (MMRp ...

GSK plc (LSE/NYSE: GSK), a prominent pharmaceutical company with a market capitalization of $71.31 billion and an impressive gross profit margin of 72.39%, has announced that its new drug applications ...

(Alliance News) - GSK PLC on Monday said the European Commission has expanded approval for its drug Jemperli, in combination with chemotherapy, to include all adult patients with primary advanced or ...

The surgical management of endometrial cancer has been markedly changed by minimally invasive techniques. After three decades of laparoscopy, robotic surgery has built upon and expanded the ...

Background Endometrial cancer is the most common gynecologic malignancy in developed countries. Trop-2 is a glycoprotein involved in cellular signal transduction and is differentially ...

GSK (GSK) and the University of Oxford announced that they have entered a new research collaboration focused on the potential of cancer ...

GSK (NYSE:GSK) announced Tuesday that the EU drug regulator has agreed to review depemokimab, an experimental monoclonal antibody targeting a class of cell signaling molecules called interleukin-5, ...